Min Sung Chung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Min Sung Chung has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Chihwan Cha
Department of Surgery, Hanyang University College of Medicine, Seoul, Republic of Korea
7 shared publications - Yongsoon Park
Department of Food and Nutrition, Hanyang University, Seoul, Korea
5 shared publications - Kiseok Jang
Department of Pathology, Hanyang University College of Medicine, Seoul 04763, Korea
4 shared publications - Su-Jin Shin
Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
4 shared publications Chihwan Cha
Hanyang University Medical Center
3 shared publicationsHanpyo Hong
Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea
3 shared publications
Latest Publications
- Open Access
- 12 December 2025
- Published by Elsevier in The Breast
- Vol. 85, 104675
Impact of the interruption of tamoxifen for pregnancy on the recurrence and survival outcomes among young women with breast cancer
- 12 December 2025
- Published by Elsevier in The Breast
- Vol. 85, 104675
Open AccessImpact of the interruption of tamoxifen for pregnancy on the recurrence and survival outcomes among young women with breast cancer
- Open Access
- 26 March 2025
- Published by Springer Nature in npj Breast Cancer
- Vol. 11 (1) , 1-6
Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status
We aimed to investigate the differences in prognosis between patients with HER2-low and HER2-zero status. This retrospective cohort study conducted at multi-institution included 1627 patients diagnosed with HER2-low or HER2-zero breast cancer (stages I–III). Survival analysis after propensity score matching was used. In total, 445 patients with HER2-low and 707 patients with HER2-zero status were included. The median follow-up was 92.7 months. Locoregional and distant recurrence-free survival were comparable between patients with HER2-low and HER2-zero status (p = 0.872, p = 0.746, respectively). HER2-low status did not affect overall survival. However, in subgroups with lymph node metastases, patients with HER2-low status showed better recurrence-free survival compared with that of patients with HER2-zero status (p = 0.033). In conclusion, survival outcomes were comparable between patients with HER2-low and HER2-zero breast cancer. More studies are needed to validate our findings and examine the biological mechanism underlying these prognostic differences.
- 26 March 2025
- Published by Springer Nature in npj Breast Cancer
- Vol. 11 (1) , 1-6
Open AccessPrognostic difference between early breast cancer patients with HER2 low and HER2 zero status
We aimed to investigate the differences in prognosis between patients with HER2-low and HER2-zero status. This retrospective cohort study conducted at multi-institution included 1627 patients diagnosed with HER2-low or HER2-zero breast cancer (stages I–III). Survival analysis after propensity score matching was used. In total, 445 patients with HER2-low and 707 patients with HER2-zero status were included. The median follow-up was 92.7 months. Locoregional and distant recurrence-free survival were comparable between patients with HER2-low and HER2-zero status (p = 0.872, p = 0.746, respectively). HER2-low status did not affect overall survival. However, in subgroups with lymph node metastases, patients with HER2-low status showed better recurrence-free survival compared with that of patients with HER2-zero status (p = 0.033). In conclusion, survival outcomes were comparable between patients with HER2-low and HER2-zero breast cancer. More studies are needed to validate our findings and examine the biological mechanism underlying these prognostic differences.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Breast Cancer
- Vol. 28 (6) , 437-447
A Randomized Trial of Sentinel Node Biopsy Omission After Neoadjuvant Systemic Therapy in Clinically Node-Negative or Selected Node-Positive Breast Cancer
Jung JJ, et al. J Breast Cancer. 2025 Nov;28:e42. https://doi.org/10.4048/jbc.2025.0157
- 1 January 2025
- Published by XMLink in Journal of Breast Cancer
- Vol. 28 (6) , 437-447
Open AccessA Randomized Trial of Sentinel Node Biopsy Omission After Neoadjuvant Systemic Therapy in Clinically Node-Negative or Selected Node-Positive Breast Cancer
Jung JJ, et al. J Breast Cancer. 2025 Nov;28:e42. https://doi.org/10.4048/jbc.2025.0157
- 27 April 2024
- Published by Springer Nature in Breast Cancer
- Vol. 31 (4) , 717-725
Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis
Background It is well known that adjuvant tamoxifen treatment for breast cancer in postmenopausal women decreased bone loss. However, the effects of adjuvant tamoxifen therapy on bone mineral density (BMD) in premenopausal patients with breast cancer remains uncertain. Tamoxifen would have a potential impact of premenopausal BMD on health. The aim of this meta-analysis was to assess this in premenopausal women with primary breast cancer. Methods Through April 2020, studies reporting BMD changes of lumbar spine or hip in premenopausal women with primary breast cancer treated with adjuvant tamoxifen and tamoxifen plus chemotherapy or ovarian function suppression (OFS) were collected from EMBASE and PubMed. The meta-analysis was performed using random effects model of the standardized mean difference (SMD) of BMD in patients. Results A total of 1432 premenopausal patients were enrolled in eight studies, involving 198 patients treated with tamoxifen alone in three studies. After a 3-year median follow-up, adjuvant tamoxifen decreased the lumbar spinal and hip BMD by as much as an SMD of −1.17 [95% confidence interval (CI); −1.58 to −0.76)] and −0.66 (95% CI, −1.55 to 0.23), respectively. In subgroup analysis in patients treated adjuvant tamoxifen and tamoxifen plus chemotherapy or OFS according to follow-up duration, the bone change of < 3 years follow-up group was −0.03 SMD (95% CI, −0.47 to 0.41) and that of ≥ 3 years follow-up group was −1.06 SMD (95% CI, −1.48 to −0.64). Compared with patients who received tamoxifen alone, patients who received combination therapy with chemotherapy or OFS showed lesser bone loss at the lumbar spine. Conclusions Our meta-analysis demonstrated that adjuvant tamoxifen therapy in premenopausal patients caused bone loss after 3 years of follow-up, especially at the lumbar spines. For a definite evaluation of the adverse effects of tamoxifen on bone, it is necessary to accumulate more relevant studies.
- 27 April 2024
- Published by Springer Nature in Breast Cancer
- Vol. 31 (4) , 717-725
Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis
Background It is well known that adjuvant tamoxifen treatment for breast cancer in postmenopausal women decreased bone loss. However, the effects of adjuvant tamoxifen therapy on bone mineral density (BMD) in premenopausal patients with breast cancer remains uncertain. Tamoxifen would have a potential impact of premenopausal BMD on health. The aim of this meta-analysis was to assess this in premenopausal women with primary breast cancer. Methods Through April 2020, studies reporting BMD changes of lumbar spine or hip in premenopausal women with primary breast cancer treated with adjuvant tamoxifen and tamoxifen plus chemotherapy or ovarian function suppression (OFS) were collected from EMBASE and PubMed. The meta-analysis was performed using random effects model of the standardized mean difference (SMD) of BMD in patients. Results A total of 1432 premenopausal patients were enrolled in eight studies, involving 198 patients treated with tamoxifen alone in three studies. After a 3-year median follow-up, adjuvant tamoxifen decreased the lumbar spinal and hip BMD by as much as an SMD of −1.17 [95% confidence interval (CI); −1.58 to −0.76)] and −0.66 (95% CI, −1.55 to 0.23), respectively. In subgroup analysis in patients treated adjuvant tamoxifen and tamoxifen plus chemotherapy or OFS according to follow-up duration, the bone change of < 3 years follow-up group was −0.03 SMD (95% CI, −0.47 to 0.41) and that of ≥ 3 years follow-up group was −1.06 SMD (95% CI, −1.48 to −0.64). Compared with patients who received tamoxifen alone, patients who received combination therapy with chemotherapy or OFS showed lesser bone loss at the lumbar spine. Conclusions Our meta-analysis demonstrated that adjuvant tamoxifen therapy in premenopausal patients caused bone loss after 3 years of follow-up, especially at the lumbar spines. For a definite evaluation of the adverse effects of tamoxifen on bone, it is necessary to accumulate more relevant studies.
- Open Access
- 20 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 14355
ASAP1 Expression in Invasive Breast Cancer and Its Prognostic Role
Breast cancer is a major global health burden with high morbidity and mortality rates. Previous studies have reported that increased expression of ASAP1 is associated with poor prognosis in various types of cancer. This study was conducted on 452 breast cancer patients who underwent surgery at Hanyang University Hospital, Seoul, South Korea. Data on clinicopathological characteristics including molecular pathologic markers were collected. Immunohistochemical staining of ASAP1 expression level were used to classify patients into high and low groups. In total, 452 cases low ASAP1 expression group was associated with significantly worse recurrence-free survival (p = 0.029). In ER-positive cases (n = 280), the low ASAP1 expression group was associated with significantly worse overall survival (p = 0.039) and recurrence-free survival (p = 0.029). In multivariate cox analysis, low ASAP1 expression was an independent significant predictor of poor recurrence-free survival in the overall patient group (hazard ratio = 2.566, p = 0.002) and ER-positive cases (hazard ratio = 4.046, p = 0.002). In the analysis of the TCGA dataset, the low-expression group of ASAP1 protein demonstrated a significantly poorer progression-free survival (p = 0.005). This study reports that low ASAP1 expression was associated with worse recurrence-free survival in invasive breast cancer.
- 20 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 14355
Open AccessASAP1 Expression in Invasive Breast Cancer and Its Prognostic Role
Breast cancer is a major global health burden with high morbidity and mortality rates. Previous studies have reported that increased expression of ASAP1 is associated with poor prognosis in various types of cancer. This study was conducted on 452 breast cancer patients who underwent surgery at Hanyang University Hospital, Seoul, South Korea. Data on clinicopathological characteristics including molecular pathologic markers were collected. Immunohistochemical staining of ASAP1 expression level were used to classify patients into high and low groups. In total, 452 cases low ASAP1 expression group was associated with significantly worse recurrence-free survival (p = 0.029). In ER-positive cases (n = 280), the low ASAP1 expression group was associated with significantly worse overall survival (p = 0.039) and recurrence-free survival (p = 0.029). In multivariate cox analysis, low ASAP1 expression was an independent significant predictor of poor recurrence-free survival in the overall patient group (hazard ratio = 2.566, p = 0.002) and ER-positive cases (hazard ratio = 4.046, p = 0.002). In the analysis of the TCGA dataset, the low-expression group of ASAP1 protein demonstrated a significantly poorer progression-free survival (p = 0.005). This study reports that low ASAP1 expression was associated with worse recurrence-free survival in invasive breast cancer.
- Open Access
- 27 July 2023
- Published by Elsevier in Current Developments in Nutrition
- Vol. 7, 100482
P13-026-23 Intake of Fermented Products Was Associated With the Risk of Cancer Recurrence and Mortality in Breast Cancer Survivors: A Prospective Cohort Study
- 27 July 2023
- Published by Elsevier in Current Developments in Nutrition
- Vol. 7, 100482
Open AccessP13-026-23 Intake of Fermented Products Was Associated With the Risk of Cancer Recurrence and Mortality in Breast Cancer Survivors: A Prospective Cohort Study
- Open Access
Prognostic Implication of YY1 and CP2c Expression in Patients with Primary Breast Cancer
Yin Yang 1 (YY1) is a transcription factor that regulates epigenetic pathways and protein modifications. CP2c is a transcription factor that functions as an oncogene to regulate cell proliferation. YY1 is known to interact with CP2c to suppress CP2c’s transcriptional activity. This study aimed to investigate YY1 and CP2c expression in breast cancer and prognostic implications. In this study, YY1 and CP2c expression was evaluated using immunohistochemical staining, Western blot and RT-PCR assays. Of 491 patients with primary breast cancer, 138 patients showed YY1 overexpression. Luminal subtype and early stage were associated with overexpression (p < 0.001). After a median follow-up of 68 months, YY1 overexpression was found to be associated with a better prognosis (disease-free survival rates of 92.0% vs. 79.2%, p = 0.014). In Cox proportional hazards model, YY1 overexpression functioned as an independent prognostic factor after adjustment of hormone receptor/HER2 status and tumor size (hazard ratio of 0.50, 95% CI 0.26–0.98, p = 0.042). Quantitative analysis of YY1 and CP2c protein expression in tumors revealed a negative correlation between them. In conclusion, YY1 overexpression is a favorable prognostic biomarker in patients with breast cancer, and it has a negative correlation with CP2c at the protein level.
Open AccessPrognostic Implication of YY1 and CP2c Expression in Patients with Primary Breast Cancer
Yin Yang 1 (YY1) is a transcription factor that regulates epigenetic pathways and protein modifications. CP2c is a transcription factor that functions as an oncogene to regulate cell proliferation. YY1 is known to interact with CP2c to suppress CP2c’s transcriptional activity. This study aimed to investigate YY1 and CP2c expression in breast cancer and prognostic implications. In this study, YY1 and CP2c expression was evaluated using immunohistochemical staining, Western blot and RT-PCR assays. Of 491 patients with primary breast cancer, 138 patients showed YY1 overexpression. Luminal subtype and early stage were associated with overexpression (p < 0.001). After a median follow-up of 68 months, YY1 overexpression was found to be associated with a better prognosis (disease-free survival rates of 92.0% vs. 79.2%, p = 0.014). In Cox proportional hazards model, YY1 overexpression functioned as an independent prognostic factor after adjustment of hormone receptor/HER2 status and tumor size (hazard ratio of 0.50, 95% CI 0.26–0.98, p = 0.042). Quantitative analysis of YY1 and CP2c protein expression in tumors revealed a negative correlation between them. In conclusion, YY1 overexpression is a favorable prognostic biomarker in patients with breast cancer, and it has a negative correlation with CP2c at the protein level.
- 12 March 2023
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 75 (4) , 1189-1199
Association of Fermented Products with Risk of Cancer Recurrence and Mortality among Breast Cancer Survivors: A Prospective Cohort Study
We hypothesized that the intake of fermented soy and dairy products, but not fermented vegetable products, was associated with reduced cancer recurrence and mortality in breast cancer survivors. Women (n = 606) who underwent dietary survey using a 24-h recall within 3 years of breast cancer surgery were recruited, and were followed up for a mean of 89 mo,. Cox proportional hazards regression analysis showed that the risk of cancer recurrence was inversely associated with the intake of fermented soy products (Hazard ratios (HRs):0.976, 95% confidence intervals (CI):0.95–0.99) and fermented dairy products (HRs:0.992, 95% CI:0.98–0.99). Furthermore, the risk of cancer recurrence was inversely associated with the intake of fermented soy products in hormone receptor-positive (HRs:0.296, 95% CI:0.11–0.79), estrogen receptor-positive (HRs:0.971, 95% CI:0.94–0.99), and progesterone receptor-positive (HRs:0.972, 95% CI:0.94–0.99) patients. Mortality was inversely associated with the intake of fermented soy products (HRs:0.967, 95% CI:0.93–0.99). Disease-free survival (P = 0.001) and overall survival (P = 0.004) were positively associated with intake of fermented soy products. Intake of fermented vegetable products had no significant effect on cancer recurrence or mortality. This study suggests that the intake of fermented soy and dairy could be beneficial in preventing cancer recurrence.
- 12 March 2023
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 75 (4) , 1189-1199
Association of Fermented Products with Risk of Cancer Recurrence and Mortality among Breast Cancer Survivors: A Prospective Cohort Study
We hypothesized that the intake of fermented soy and dairy products, but not fermented vegetable products, was associated with reduced cancer recurrence and mortality in breast cancer survivors. Women (n = 606) who underwent dietary survey using a 24-h recall within 3 years of breast cancer surgery were recruited, and were followed up for a mean of 89 mo,. Cox proportional hazards regression analysis showed that the risk of cancer recurrence was inversely associated with the intake of fermented soy products (Hazard ratios (HRs):0.976, 95% confidence intervals (CI):0.95–0.99) and fermented dairy products (HRs:0.992, 95% CI:0.98–0.99). Furthermore, the risk of cancer recurrence was inversely associated with the intake of fermented soy products in hormone receptor-positive (HRs:0.296, 95% CI:0.11–0.79), estrogen receptor-positive (HRs:0.971, 95% CI:0.94–0.99), and progesterone receptor-positive (HRs:0.972, 95% CI:0.94–0.99) patients. Mortality was inversely associated with the intake of fermented soy products (HRs:0.967, 95% CI:0.93–0.99). Disease-free survival (P = 0.001) and overall survival (P = 0.004) were positively associated with intake of fermented soy products. Intake of fermented vegetable products had no significant effect on cancer recurrence or mortality. This study suggests that the intake of fermented soy and dairy could be beneficial in preventing cancer recurrence.
- Open Access
- 2 February 2023
- Published by Springer Nature in Research Square
Prognostic implication of YY1 and CP2c expression in patients with primary breast cancer
Background YY1 is transcription factor that regulates differential epigenetic pathways and protein modifications. CP2c is transcription factor that functions as oncogene to regulate cancer cell proliferation. YY1 is known to interact with CP2c to suppress CP2c’s transcriptional activity. However, it is unknown whether YY1 has prognostic significance in breast cancer. Thus, we aimed to investigate YY1 and CP2c expression in breast cancer and prognostic implications. Methods Clinical information and tissues were obtained from 491 patients with invasive breast cancer. YY1 expression was evaluated using immunohistochemical staining and patients were divided into two groups according to H-score. Western blot and RT-PCR assays were used for quantifications of YY1 and CP2c mRNA and protein expression. Results Of 491 patients with breast cancer, 138 patients showed YY1 overexpression. Luminal subtype, and early stage were associated with overexpression. After follow-up of 68 months, YY1 overexpression was found to be associated with better prognosis. In Cox proportional hazards model, YY1 overexpression functioned as independent prognostic factor after adjustment of ER/HER2 status and tumor size. Quantitative analysis of YY1 and CP2c protein expression in tumor revealed negative correlation between them. Conclusions YY1 overexpression is a favorable prognostic biomarker in patients with breast cancer, and it has negative correlation with CP2c.
- 2 February 2023
- Published by Springer Nature in Research Square
Open AccessPrognostic implication of YY1 and CP2c expression in patients with primary breast cancer
Background YY1 is transcription factor that regulates differential epigenetic pathways and protein modifications. CP2c is transcription factor that functions as oncogene to regulate cancer cell proliferation. YY1 is known to interact with CP2c to suppress CP2c’s transcriptional activity. However, it is unknown whether YY1 has prognostic significance in breast cancer. Thus, we aimed to investigate YY1 and CP2c expression in breast cancer and prognostic implications. Methods Clinical information and tissues were obtained from 491 patients with invasive breast cancer. YY1 expression was evaluated using immunohistochemical staining and patients were divided into two groups according to H-score. Western blot and RT-PCR assays were used for quantifications of YY1 and CP2c mRNA and protein expression. Results Of 491 patients with breast cancer, 138 patients showed YY1 overexpression. Luminal subtype, and early stage were associated with overexpression. After follow-up of 68 months, YY1 overexpression was found to be associated with better prognosis. In Cox proportional hazards model, YY1 overexpression functioned as independent prognostic factor after adjustment of ER/HER2 status and tumor size. Quantitative analysis of YY1 and CP2c protein expression in tumor revealed negative correlation between them. Conclusions YY1 overexpression is a favorable prognostic biomarker in patients with breast cancer, and it has negative correlation with CP2c.
- Open Access
- 3 August 2022
- Published by Springer Nature in Research Square
Adverse Effects of Tamoxifen Treatment on Bone Mineral Density in Premenopausal Patients with Breast Cancer: A Systematic Review and Meta-Analysis
The effects of adjuvant tamoxifen therapy on bone mineral density (BMD) in premenopausal patients with breast cancer remains uncertain and, the aim of this meta-analysis was to assess this in premenopausal women with primary breast cancer. Through April 2020, studies reporting BMD changes of lumbar spine or hip in premenopausal women with primary breast cancer treated with adjuvant tamoxifen and tamoxifen plus chemotherapy or ovarian function suppression (OFS) were collected from EMBASE and PubMed. The pooled analysis was performed using random effects model of the standardized mean difference (SMD) of BMD in patients. A total of 1,432 premenopausal patients from eight studies were included. After a 3-year median follow-up, adjuvant tamoxifen decreased the lumbar spinal and hip BMD by as much as an SMD of -1.17 and − 0.66, respectively. Compared with patients who received tamoxifen alone, patients who received combination therapy with chemotherapy or OFS showed lower bone loss compared with tamoxifen alone at the lumbar spine. Our meta-analysis demonstrated that adjuvant tamoxifen therapy in premenopausal patients caused bone loss after 3 years of follow-up, especially at the lumbar spines. For a definite evaluation of the adverse effects of tamoxifen on bone, it is necessary to accumulate more relevant studies.
- 3 August 2022
- Published by Springer Nature in Research Square
Open AccessAdverse Effects of Tamoxifen Treatment on Bone Mineral Density in Premenopausal Patients with Breast Cancer: A Systematic Review and Meta-Analysis
The effects of adjuvant tamoxifen therapy on bone mineral density (BMD) in premenopausal patients with breast cancer remains uncertain and, the aim of this meta-analysis was to assess this in premenopausal women with primary breast cancer. Through April 2020, studies reporting BMD changes of lumbar spine or hip in premenopausal women with primary breast cancer treated with adjuvant tamoxifen and tamoxifen plus chemotherapy or ovarian function suppression (OFS) were collected from EMBASE and PubMed. The pooled analysis was performed using random effects model of the standardized mean difference (SMD) of BMD in patients. A total of 1,432 premenopausal patients from eight studies were included. After a 3-year median follow-up, adjuvant tamoxifen decreased the lumbar spinal and hip BMD by as much as an SMD of -1.17 and − 0.66, respectively. Compared with patients who received tamoxifen alone, patients who received combination therapy with chemotherapy or OFS showed lower bone loss compared with tamoxifen alone at the lumbar spine. Our meta-analysis demonstrated that adjuvant tamoxifen therapy in premenopausal patients caused bone loss after 3 years of follow-up, especially at the lumbar spines. For a definite evaluation of the adverse effects of tamoxifen on bone, it is necessary to accumulate more relevant studies.